Small cell lung cancer (SCLC) is an aggressive form of cancer that arises from the neuroendocrine cells of the lung tissue. It is characterized by rapid growth and a high rate of metastasis, which often leads to late diagnosis and poor prognosis for patients. SCLC accounts for about 10-15% of all lung cancer cases and is closely associated with smoking, although other factors can cause it. The disease progresses due to the special biology of tumor cells, which are able to divide rapidly, forming tumors that are sensitive to chemotherapy but resistant to radiotherapy. The main clinical manifestations of SCLC are cough, weight loss, shortness of breath, and pain syndrome associated with lung and other organ damage.
History of the disease and interesting historical facts
Small cell lung cancer was first described in the medical literature in the 1930s, but its international recognition as a distinct form of cancer did not occur until 1972, following the publication of a paper detailing its clinical and morphological characteristics. Interestingly, SCLC was one of the first cancer types for which chemotherapy was developed and introduced into clinical practice. Studies in the 1980s showed that a combination of chemotherapeutic drugs such as cyclophosphamide and doxorubicin provided patients with the opportunity to prolong survival and improve quality of life. Subsequently, new chemotherapy regimens were developed and introduced, which significantly improved treatment outcomes.
Epidemiology
According to the World Health Organization, SCLC has a heterogeneous distribution by region. About 1.8 million new cases of lung cancer are registered annually in the world, of which approximately 10-15% are small cell forms. According to statistics, the incidence of SCLC is significantly higher among men than among women, even in countries with low smoking rates among women. The risk of developing this disease increases with age, and the analgesic group of people over 60 years old constitutes the majority of patients. In recent years, there has been a tendency for the incidence to increase among non-smokers, which requires further study of exogenous and endogenous risk factors.
Genetic predisposition to this disease
Genetic changes play a significant role in the pathogenesis of small cell lung cancer. Studies show that among the genes involved are TP53, Rb1 and other genes associated with cell cycle regulation and apoptosis. Mutations in the TP53 gene are observed in more than 90% patients with SCLC. Studies also indicate the presence of specific chromosomal abnormalities, such as deletions on chromosome 3p and 5q, which may also indicate a high mutational load of the tumor. Familial cases of lung cancer have also been recorded, confirming the presence of a genetic predisposition to this disease.
Risk factors for the development of this disease
Risk factors for the development of small cell lung cancer can be classified into physical and chemical. The main factors include:
- Smoking is the main risk factor, including active and passive smoking.
- Exposure to carcinogens such as asbestos, radon and polonium.
- Environmental factors including air pollution and exposure to chemicals in industrial settings.
- Pre-existing lung diseases, such as chronic obstructive pulmonary disease (COPD).
- Age - the risk of developing the disease increases significantly with age.
Patients working in hazardous industrial sectors are also at increased risk, requiring monitoring of their health.
Diagnosis of this disease
Diagnosis of small cell lung cancer involves several levels of examination and laboratory tests. The main symptoms of the disease are:
- Cough, often with discharge and blood.
- Shortness of breath and breathing noise.
- Loss of appetite and weight.
- Chest pain, especially when taking deep breaths.
Laboratory tests are performed to confirm the diagnosis and evaluate lung function, including:
- Morphological studies - biopsy of lung tissue followed by histological analysis.
- Clinical and biochemical blood tests.
- Immunohistochemical analysis to determine characteristic markers.
Radiological examinations such as X-ray, computed tomography and magnetic resonance imaging allow visualization of the tumor and its metastasis. The differential diagnosis with other lung diseases such as adenocarcinoma and squamous cell carcinoma, which require different treatment approaches, completes the diagnosis.
Treatment
Treatment of SCLC should begin with a comprehensive approach, including pharmacological, surgical and radiation therapy. The extent of surgical intervention is determined by the stage of the disease. In the early stages of the disease, lung resection or even pleurectomy can be performed. However, most often, patients with SCLC seek treatment at late stages, when the tumor metastasizes, which requires the appointment of chemotherapy based on combined regimens.
Chemotherapy involves the use of drugs such as cisplatin and etoposide and usually produces a good response to treatment. New immunotherapy methods such as checkpoint inhibitors are also being actively introduced into clinical practice and are showing encouraging results. However, it should be noted that due to the aggressive nature of this cancer, the prognosis remains grave.
List of medications used to treat this disease
Various drugs are used in the treatment of small cell lung cancer. The main ones are:
- Cisplatin
- etoposide
- Doxorubicin
- Immuno-oncology agents such as nivolumab
- Topotecan used for relapse of the disease
Each of these drugs has its own indications, contraindications and side effects that must be taken into account during the treatment process.
Disease monitoring
Monitoring during and after treatment is critical. Regular follow-up examinations help identify relapses and assess the effectiveness of therapy. The recommended schedule includes:
- Clinical examination every 3-6 months during the first 2-3 years after treatment.
- Chest CT scan every 6-12 months.
- Laboratory tests to monitor general health.
The prognosis for patients with small cell lung cancer is generally poor, especially if the disease is diagnosed at an advanced stage. Complications may include metastasis to the brain and other organs, which requires treatment.
Age-related features of the disease
Small cell lung cancer is most often diagnosed in people over 60 years of age. In this age group, the disease has its own characteristics, such as a more aggressive course and a high probability of metastasis. Older patients often have concomitant diseases, which makes treatment more difficult and less effective.
However, in recent years there has been an increase in cases among younger people, which may be due to both an increase in incidence among women and environmental factors.
Questions and Answers
- What are the main symptoms of small cell lung cancer? The main symptoms are cough, shortness of breath, chest pain and weight loss.
- Can small cell lung cancer be prevented? Stopping smoking and reducing exposure to carcinogens can reduce the risk.
- How is this disease diagnosed? Diagnostics includes morphological studies, clinical and radiological examinations.
- What treatments are used for small cell lung cancer? Treatment includes chemotherapy, surgery and immunotherapy.
- What is the prognosis for patients with small cell lung cancer? The prognosis is generally unfavorable, but depends on the stage of the disease at the time of diagnosis.
Thus, understanding small cell lung cancer and its characteristics helps in diagnosis and treatment, which may ultimately lead to improved outcomes for patients.
